Neurotech just had a hell of a fortnight. Here's where the money went:
* Sergey Brin's Nexus NeuroTech Ventures folded into family office Bayshore Global Management, 15-company portfolio intact
* Ground Effect Ventures launched immediately as its replacement in the BrainTech Alliance
* Newfund closes €60M dedicated brain tech fund out of Paris
* ARPA-H commits $139M for behavioural health through the EVIDENT initiative
* Cala Health secures $50M growth capital for its FDA-cleared wearable tremor device
* ONWARD Medical raises €40.6M, runway extended to Q1 2028
* Nervonik closes oversubscribed $52.5M Series B for closed-loop peripheral nerve stimulation
* Harvard neuroscientist Gabriel Kreiman leaves academia to raise $100M at $1B valuation for AI memory startup
* Click Therapeutics and Boehringer Ingelheim announce Series D for digital therapeutic targeting schizophrenia
* NightWare closes $1.4M to expand VA Pathfinder Pilot and first responder coverage
* Jetstream Venture Fund secures positions in Surf Therapeutics and Hill Research
A few things stand out when you look at this together.
The Brin move isn't an exit, it's a consolidation. Pulling $200M of neurotech bets closer to the family office while the former fund team immediately launches a replacement suggests conviction, not retreat.
The capital is maturing. Most of these rounds are going into commercialisation-stage, FDA-cleared devices looking to scale. That's a different risk profile from the speculative early-stage rounds that dominated neurotech two or three years ago.
Dedicated neurotech investment vehicles are multiplying. Family offices, European early-stage funds, government-backed programmes. The sector is building its own financial architecture rather than relying on generalist medtech or biotech funds to show up.
Behavioural health is getting serious money. ARPA-H's $139M and the Click Therapeutics Series D both point to mental health moving from research priority to genuine commercial priority.
The wildcard is Kreiman. Memory is one of the least commercially developed areas in neurotech and one of the most interesting given the scale of Alzheimer's and cognitive decline globally. Worth watching.
Anyone investing in Neurotech?